Down's | Search

临床试验

计划入组 180 人 · 首次发布于 2005 年 10 月 18 日

已完成

NCT06234644

Effects of Maze Activities in Down's Syndrome

计划入组 26 人 · 首次发布于 2024 年 1 月 31 日

已完成

NCT01758718

Eyelash Line Resection for Entropion Associated With Down's Syndrome

计划入组 24 人 · 首次发布于 2013 年 1 月 1 日

药物

查看全部 10 →

L-41

Biotech

Approved

St. John's Wort

相关疾病：Anxiety, Burns first degree，另有 9 项

therapeutic (Alzheimers disease/Down syndrome)

机构

查看全部 8 →

DARLING DOWNS HOSPITAL AND HEALTH SERVICE

Australia

Saint John's Cancer Institute

United States

ST JOHN'S RESEARCH INSTITUTE

India

资讯

查看全部 102 →

去年

STALICLA Appoints Dr. Paulo Fontoura as Chief Scientific and Clinical Development Advisor

去年

CONNECTA Therapeutics Advances First-in-Class Neuroplasticity Modulator CTH120 to Phase II for Pediatric Fragile X Syndrome

去年

临床试验

Memantine and Down's Syndrome

Effects of Maze Activities in Down's Syndrome

Eyelash Line Resection for Entropion Associated With Down's Syndrome

药物

L-41

St. John's Wort

therapeutic (Alzheimers disease/Down syndrome)

机构

DARLING DOWNS HOSPITAL AND HEALTH SERVICE

Saint John's Cancer Institute

ST JOHN'S RESEARCH INSTITUTE

资讯

STALICLA Appoints Dr. Paulo Fontoura as Chief Scientific and Clinical Development Advisor

CONNECTA Therapeutics Advances First-in-Class Neuroplasticity Modulator CTH120 to Phase II for Pediatric Fragile X Syndrome

Immutep's LAG-3 Agonist Shows Promise, Percheron and PYC Update on Neurological Disease Trials